Sanofi SA

US Senator Bernie Sanders, Independent of Vermont, speaks during a rally by the People's Action, protesting pharmaceutical companies' lobbying against allowing Medicare to negotiate lower prescription drug prices, outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, DC, September 21, 2021.Saul Loeb | AFP | Getty ImagesThe CEOs of Merck and Johnson & Johnson have voluntarily agreed to testify at an upcoming Senate hearing on high drug prices in the U.S., Sen. Bernie Sanders…

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty ImagesDrugmakers have been scrambling to join a two-horse race to lead the market for popular weight loss drugs, which could be worth tens of billions in less than a decade.Demand is only expected to grow, leaving room in the segment for lesser-known weight loss drug hopefuls such as the privately held German drugmaker…

Medical personnel use a mammogram to examine a woman's breast for breast cancer.Hannibal Hanschke | dpa | Picture Alliance | Getty ImagesSAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead.That was one clear takeaway from the JPMorgan Healthcare Conference in San Francisco, the nation's largest gathering of biotech and pharmaceutical executives, analysts and investors. During the four-day event,…

Sopa Images | Lightrocket | Getty ImagesPfizer's twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug lost significant weight but experienced high rates of adverse side effects in a midstage clinical trial. Pfizer noted that it will release data on a once-daily version of…

A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children's clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | ReutersThe Centers for Disease Control and Prevention expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from respiratory syncytial virus amid an ongoing shortage of the treatment in the U.S.The CDC's move late Thursday to increase the availability of Beyfortus, a monoclonal antibody from…

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy.Stefan Trumpf | Picture Alliance | Getty ImagesU.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk's Wegovy and Ozempic after some patients who took the treatments reported thoughts of suicide or self-harm.The probe into potentially life-threatening side effects comes as the drugs skyrocket in popularity in the U.S. — and draw heightened…

A doctor is injecting a vaccine to a baby boyKarl Tapales | Moment | Getty ImagesSanofi expects its infant RSV shot to roll out in the U.S. before respiratory virus season this fall, a company spokesperson said Friday.The Food and Drug Administration on Monday approved Beyfortus, a monoclonal antibody that is administered as a single dose to infants before or during their first respiratory syncytial virus season.The Sanofi spokesperson said the company does not expect any challenges with manufacturing or capacity to meet…

Blood sample for respiratory syncytial virus (RSV) testJarun011 | Istock | Getty ImagesThe Food and Drug Administration on Monday approved AstraZeneca and Sanofi's shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among babies in the U.S.Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition.related investing newsThe FDA approval of nirsevimab comes…

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.Mike Segar | ReutersUninsured Americans pay nearly $98 on average for a vial of Eli Lilly's generic insulin, even after the company pledged to cut the product's list price to $25 per vial, according to a report released Thursday by Sen. Elizabeth Warren.Eli Lilly earlier this year vowed to slash the list price of its generic insulin, Lispro, from $82.42 per vial starting on May 1. The…

Nikos Pekiaridis | Nurphoto | Getty ImagesModerna on Wednesday said it struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China. The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop drugs that will "be exclusively for the Chinese people" and "not be exported," a Moderna spokesperson told CNBC.  Chinese media outlet Yicai first reported on…